SCHEMBL21340751

SCHEMBL21340751

CNc1ccc(OCc2cccc(F)c2)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.53
GAK O14976 1/20 0.53
MAOB P27338 1/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 3/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
PABPC1 P11940 1/20 0.50
CTSV O60911 2/20 0.48
CTSL P07711 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ERBB2 P04626 4/20 0.47
KDM4E B2RXH2 1/20 0.46
PLA2G1B P04054 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.45
CSF1R P07333 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22967590 0.87 EGFR (0.52) EGFRGAKMAOBMEN1KMT2A
SCHEMBL6979972 0.86 LMNA (0.50) EGFRGAKMAOBLMNAALDH1A1
SCHEMBL22967587 0.86 EGFR (0.51) EGFRGAKMAOBMEN1KMT2A
SCHEMBL6980764 0.85 MRGPRX4 (0.54) EGFRGAKMAOBLMNAALDH1A1
SCHEMBL9975357 0.84 EGFR (0.65) EGFRGAKERBB2
SCHEMBL22967643 0.83 EGFR (0.48) EGFRGAKMAOBMEN1KMT2A
SCHEMBL12864874 0.82 MAOB (0.56) EGFRGAKMAOBMEN1KMT2A
SCHEMBL14548610 0.82 LMNA (0.52) EGFRGAKMAOBLMNAALDH1A1
SCHEMBL4333127 0.81 TSHR (0.51) EGFRALDH1A1SMN1; SMN2CTSVCTSL
SCHEMBL1406548 0.81 MAOB (0.60) EGFRGAKMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 EP disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed
EP-3760633-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-01-06 EP disclosed
WO-2019170088-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF 北京赛特明强医药科技有限公司 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 EGFR 3163/4885GAK 174/4885MAOB 975/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 EGFR 3163/4885GAK 174/4885MAOB 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.